Infliximab for the treatment of severe pustular psoriasis: 6 Years later

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 10, 2008, Pages 1253-1254

  Varma, R ^a   Cantrell, W ^a   Elmets, C ^a   Elewski, B ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; DISEASE SEVERITY; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 51649104013     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02596.x     Document Type: Letter

References (5)

1. Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002 47 : 796 797.
2. US Food and Drug Administration [Internet Website]. Remicade (infliximab) package insert. Centocor Inc, Malvern, PA, 2006. [updated November 10, 2006; cited February 19, 2007] Available from: http://www.fda.gov/cder/foi/label/2006/ 103772s5163lbl.pdf.
3. Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol 2006 5 : 546 548.
4. Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005 52 : 736 737.
5. Menter A, Feldman S, Weinstein G et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 31 44.